Stock IRWD IRONWOOD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
7.82 USD -3.22% Intraday chart for Ironwood Pharmaceuticals, Inc. -1.26% -31.64%
Mar. 28 Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) CI
Feb. 29 Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,087 1,824 1,908 1,901 1,786 1,243 - -
Enterprise Value (EV) 1 2,318 1,894 1,742 1,641 1,786 1,243 1,243 1,243
P/E ratio 95.1 x 17.3 x 3.63 x 12.9 x -1.77 x 10.1 x 8.89 x 5.97 x
Yield - - - - - - - -
Capitalization / Revenue 4.87 x 4.68 x 4.61 x 4.63 x 4.03 x 2.77 x 2.52 x 2.14 x
EV / Revenue 4.87 x 4.68 x 4.61 x 4.63 x 4.03 x 2.77 x 2.52 x 2.14 x
EV / EBITDA 14.1 x 11.3 x 8.16 x 7.55 x -2.02 x 7.92 x 6.4 x 4.29 x
EV / FCF -3,038 x 10.9 x 7.29 x 6.95 x 9.75 x 6.81 x 6.69 x 5.24 x
FCF Yield -0.03% 9.16% 13.7% 14.4% 10.3% 14.7% 14.9% 19.1%
Price to Book -22.6 x 29.2 x 3.12 x 3.54 x - - - -
Nbr of stocks (in thousands) 156,818 160,097 163,650 153,395 156,129 158,957 - -
Reference price 2 13.31 11.39 11.66 12.39 11.44 7.820 7.820 7.820
Announcement Date 2/13/20 2/17/21 2/17/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 428.4 389.5 413.8 410.6 442.7 448.2 493.9 581.4
EBITDA 1 147.8 160.7 233.7 251.8 -884.8 156.9 194.1 289.5
EBIT 1 120.1 142.9 232.2 250.3 -945.4 153.4 186.8 272.1
Operating Margin 28.04% 36.7% 56.12% 60.97% -213.54% 34.22% 37.81% 46.8%
Earnings before Tax (EBT) 1 21.5 108.9 200.7 252.4 -948.1 128.6 176.8 243
Net income 1 21.5 106.2 528.4 175.1 -1,002 105.7 138.7 195.7
Net margin 5.02% 27.26% 127.72% 42.64% -226.37% 23.58% 28.08% 33.66%
EPS 2 0.1400 0.6600 3.210 0.9600 -6.450 0.7767 0.8800 1.310
Free Cash Flow 1 -0.687 167 261.6 273.6 183.2 182.4 185.7 237
FCF margin -0.16% 42.87% 63.23% 66.64% 41.37% 40.7% 37.61% 40.76%
FCF Conversion (EBITDA) - 103.93% 111.93% 108.69% - 116.28% 95.69% 81.87%
FCF Conversion (Net income) - 157.28% 49.51% 156.3% - 172.6% 133.91% 121.1%
Dividend per Share - - - - - - - -
Announcement Date 2/13/20 2/17/21 2/17/22 2/16/23 2/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 103.7 117.1 97.53 97.23 108.6 107.2 104.1 107.4 113.7 117.6 106.2 112.1 114.8 114.3 109.8
EBITDA 1 65.46 56.95 - 56.02 68.84 68.7 60.38 -1,034 49.08 39.9 32.2 37.25 40.2 38.95 37
EBIT 1 65.1 56.59 57.85 55.66 68.47 68.36 60.1 20.32 40.02 37.59 31.52 41.58 40.58 41.82 36.9
Operating Margin 62.75% 48.32% 59.31% 57.24% 63.03% 63.77% 57.75% 18.92% 35.19% 31.98% 29.67% 37.07% 35.36% 36.6% 33.62%
Earnings before Tax (EBT) 1 59.67 46.26 56.46 53.78 69.91 72.26 65.86 -1,076 31.93 30.36 27.4 36.8 34.77 38.93 27.6
Net income 1 55.84 41.37 38.8 37.08 50.32 48.87 45.71 -1,062 15.32 -1.087 27.93 31.5 28.93 33.53 22.1
Net margin 53.83% 35.32% 39.78% 38.14% 46.32% 45.59% 43.93% -989.17% 13.47% -0.92% 26.29% 28.09% 25.21% 29.34% 20.14%
EPS 2 0.3400 0.2500 0.2100 0.2100 0.2800 0.2700 0.2500 -6.840 0.0900 -0.0100 0.2033 0.2233 0.1775 0.2333 0.1400
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/17/22 5/5/22 8/4/22 11/3/22 2/16/23 5/4/23 8/8/23 11/9/23 2/15/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 231 70.8 - - - - - -
Net Cash position - - 166 260 - - - -
Leverage (Debt/EBITDA) 1.563 x 0.4408 x - - - - - -
Free Cash Flow 1 -0.69 167 262 274 183 182 186 237
ROE (net income / shareholders' equity) - - 158% 27.8% - - - -
ROA (Net income/ Total Assets) 23.3% 22.1% 62.7% 15.7% - - - -
Assets 1 92.41 481 843.1 1,114 - - - -
Book Value Per Share -0.5900 0.3900 3.740 3.500 - - - -
Cash Flow per Share 0.0700 1.050 - - - - - -
Capex 1 11.4 1.84 0.27 0.14 0.27 0.5 0.5 0.5
Capex / Sales 2.66% 0.47% 0.06% 0.03% 0.06% 0.11% 0.1% 0.09%
Announcement Date 2/13/20 2/17/21 2/17/22 2/16/23 2/15/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Ironwood Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.82 USD
Average target price
17.4 USD
Spread / Average Target
+122.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IRONWOOD PHARMACEUTICALS, INC. Stock Ironwood Pharmaceuticals, Inc.
-31.64% 1.24B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IRWD Stock
  4. Financials Ironwood Pharmaceuticals, Inc.